Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 8/20 | 0.36 |
| ▸ | MMP8 | P22894 | 7/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.35 |
| ▸ | MMP17 | Q9ULZ9 | 5/20 | 0.34 |
| ▸ | MMP2 | P08253 | 4/20 | 0.33 |
| ▸ | MMP3 | P08254 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609772 | 0.85 | GRM2 (0.47) | PKMGRM2ALDH1A1 | |
| SCHEMBL1346196 | 0.79 | PKM (0.46) | PKMMMP14MMP8MMP13GRM2 | |
| SCHEMBL1345646 | 0.79 | PKM (0.41) | PKMMMP14MMP8MMP13GRM2 | |
| SCHEMBL29161590 | 0.76 | PKM (0.40) | PKMMMP14MMP8MMP13GRM2 | |
| SCHEMBL22824347 | 0.76 | CNR2 (0.46) | PKMMMP14MMP8MMP13GRM2 | |
| SCHEMBL10308970 | 0.75 | PKM (0.49) | PKMMMP14MMP8MMP13MMP17 | |
| SCHEMBL24597279 | 0.74 | PKM (0.45) | PKMMMP14MMP8MMP13MMP17 | |
| SCHEMBL21384021 | 0.74 | PKM (0.49) | PKMMMP14MMP8MMP13MMP17 | |
| SCHEMBL22824290 | 0.73 | NPSR1 (0.36) | PKMGRM2DRD2DRD3ALDH1A1 | |
| SCHEMBL15332913 | 0.71 | PKM (0.43) | PKMMMP14MMP8MMP13MMP17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063055-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7700607-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2010-04-20 | — | — | US | disclosed |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | KIT, CMA1, C3AR1 | PKM 703/4885MMP14 3739/4885MMP8 2191/4885 |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | KIT, CMA1, C3AR1 | PKM 703/4885MMP14 3739/4885MMP8 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.